931 F.3d 1363
Fed. Cir.2019Background
- VirnetX sued Apple (and separately Cisco) claiming infringement of patents ’504 and ’211, which disclose DNS-based systems to indicate support for establishing secure communication links.
- Apple (and Cisco) requested inter partes reexaminations at the PTO challenging the patents as anticipated or obvious; the PTO Examiner rejected the claims and the Board affirmed those rejections.
- In the district litigation, a jury found infringement and no invalidity; the Federal Circuit in VirnetX I affirmed the no-invalidity findings but vacated and remanded on claim construction, infringement, and damages issues unrelated to the invalidity determinations.
- VirnetX petitioned the PTO to terminate Apple’s reexams under the pre‑AIA 35 U.S.C. § 317(b) estoppel (bar on PTO reexamination after a final court decision of no invalidity); the PTO denied termination, and the Board proceeded to affirm unpatentability of claims.
- On appeal to the Federal Circuit, the panel held (following Fairchild) that § 317(b) estoppel applies once the court has affirmed no-invalidity and the time to petition for certiorari on that invalidity determination has passed—even if other non‑validity issues were remanded—so certain Apple reexams must be terminated; the court affirmed other Board rejections that were not estopped and affirmed the Cisco reexam outcome in full.
Issues
| Issue | Plaintiff's Argument (VirnetX) | Defendant's Argument (Apple/Cisco) | Held |
|---|---|---|---|
| Whether pre‑AIA 35 U.S.C. § 317(b) estops Apple from maintaining inter partes reexaminations after this court affirmed no‑invalidity but remanded other issues | § 317(b) bars PTO reexams once a final decision on invalidity is entered and the certiorari window has passed; here the invalidity decision is final | The invalidity decision is not final because related issues were remanded and a future appeal (including potential Supreme Court review) remains possible | Estoppel applies: final decision on invalidity occurred when this court affirmed no‑invalidity and the time to petition for certiorari on that issue expired; vacate and terminate specified Apple reexams |
| Scope of § 317(b): finality requirement—issue finality vs. casewide finality | The statute requires finality only as to the invalidity issue, not the entire case; estoppel should attach when invalidity determination is finally resolved | The statute requires final judgment on the entire case or exhaustion of all appellate avenues before estoppel attaches | Court: statute targets finality of the invalidity decision; remanded issues unrelated to validity do not prevent estoppel if they cannot affect the validity ruling |
| Whether the Board shifted burden or failed to address key claim‑construction/claim‑scope arguments in affirming reexamination rejections | Board improperly construed "indication" and disparagement arguments; it shifted the burden and made new grounds lacking substantial evidence | Board followed record, addressed disavowal claim‑construction arguments, and did not improperly shift burden; examiners carried burden of proving unpatentability and Board reviewed applicant responses | Affirmed: Board’s constructions and factual findings have substantial evidence; no improper burden shift or new‑ground prejudice warranting reversal |
| Constitutionality challenge and relation to IPR rulings | Reexams are unconstitutional under arguments raised in IPR certiorari petitions | Reexams differ from IPRs; Supreme Court has rejected IPR constitutional challenges | Moot: Supreme Court’s decision in Oil States resolved related constitutional arguments against IPRs; reexams not invalidated here |
Key Cases Cited
- Bettcher Indus., Inc. v. Bunzl USA, Inc., 661 F.3d 629 (Fed. Cir.) (estoppel under reexamination provisions triggers after appeals have terminated)
- Fairchild (Taiwan) Corp. v. Power Integrations, Inc., 854 F.3d 1364 (Fed. Cir.) (a decision on invalidity is final for § 317(b) once affirmed and the certiorari period has passed, even if other unrelated issues were remanded)
- Fresenius USA, Inc. v. Baxter Int’l, Inc., 721 F.3d 1330 (Fed. Cir.) (finality for res judicata and related doctrines requires the litigation be entirely concluded; distinguishes issue‑finality contexts)
- Rambus Inc. v. Rea, 731 F.3d 1248 (Fed. Cir.) (discussing burden and standards in PTO proceedings and appeals)
- MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (U.S.) (declaratory‑judgment counterclaims of invalidity are independent of infringement and not mooted by noninfringement)
- Chevron U.S.A. Inc. v. NRDC, Inc., 467 U.S. 837 (U.S.) (framework for deference to agency statutory interpretations)